We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 650

Pharmaceutical Company Agrees to $625 Million False Claims Act Settlement
  • Jones Day
  • USA
  • October 17 2018

The civil settlement is one the largest FCA settlements in recent years. The Department of Justice ("DOJ") recently announced that it agreed with


Federal Health Fraud Penalties Are Rising Once Again
  • Reed Smith LLP
  • USA
  • October 11 2018

The Department of Health and Human Services (HHS) has just announced annual inflation-related increases to civil monetary penalties (CMPs) in its


AmeriSourceBergen Takes another Financial Hit for Fake Pharmacy Operation Under False Claims Act
  • FisherBroyles LLP
  • USA
  • October 3 2018

In a recent announcement, the Department of Justice disclosed that AmerisourceBergen Corporation and several of its subsidiaries (collectively "ABC")


Marijuana-Based Drug Is Placed On Schedule V of Controlled Substances Act
  • Jackson Lewis PC
  • USA
  • September 27 2018

The U.S. Department of Justice and Drug Enforcement Administration announced on September 27, 2018 that Epidiolex, a cannabis-based drug approved by


U.S. House legislation highlights escalating government-wide focus on opioid abuse
  • Hogan Lovells
  • USA
  • July 6 2018

On June 22 the U.S. House of Representatives passed sweeping legislation that represents "the biggest effort Congress has ever undertaken" to address


GAO Releases Report Analyzing HHS-OIG Integrity Agreements Since 2005
  • Cooley LLP
  • USA
  • May 16 2018

The U.S. Government Accountability Office (GAO) released a report on May 10th characterizing over 10 years of corporate integrity agreements and


The latest: Health Care Antitrust Enforcement Remains a Top Priority for New FTC Commissioners
  • McDermott Will & Emery
  • USA
  • May 4 2018

On April 27, 2018, the United States Senate confirmed President Trump’s five nominees for Commissioners of the Federal Trade Commission (FTC). Three


Boots on the Ground: PIL Task Force Targeting Opioid Providers in the War on Drugs
  • K&L Gates
  • USA
  • April 30 2018

Attorney General Jeff Sessions announced the creation of the Prescription Interdiction & Litigation (“PIL”) Task Force -- which Sessions described as


Developments in FDA & DOJ Regulation and Enforcement of Manufacturer Communications
  • Ropes & Gray LLP
  • USA
  • April 12 2018

The rules regarding truthful, non-misleading communications by medical product manufacturers have long been unclear. In recent years, there have been


Enforcement and Litigation Strategies: Skadden’s Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • March 29 2018

On March 15, 2018, Skadden hosted its Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar in Palo Alto, California, which focused